QuidelOrtho Corporation Common Stock
QDELQuidelOrtho Corporation (QDEL) is a global leader in the development and manufacturing of diagnostic healthcare products. The company specializes in rapid diagnostic testing solutions, including point-of-care tests for infectious diseases, cardiac health, and respiratory illnesses. Formed from the merger of Quidel Corporation and Ortho Clinical Diagnostics, QuidelOrtho offers a broad portfolio of products used in hospitals, laboratories, and clinics to facilitate timely and accurate disease detection and management.
Company News
The global pregnancy detection kits market is projected to grow from USD 1.91 billion in 2025 to USD 2.69 billion by 2031, with a CAGR of 5.87%. Growth is driven by technological advancements enabling earlier detection, rising infertility rates, and increasing adoption of digital integration and e-commerce distribution. However, the market faces ...
Rice Hall James & Associates purchased 574,877 shares of QuidelOrtho in Q4, increasing its stake to 833,791 shares valued at $23.8 million (1.3% of fund assets). The investment reflects confidence in the diagnostic technology company despite its stock being down 43.4% over the past year, as value investors anticipate improved financial results fr...
QuidelOrtho board director Matthew Strobeck purchased 10,000 shares for ~$240,000 on Feb. 13, 2026, as the company faces another executive transition with CFO Joseph Busky's retirement effective in June. The diagnostics company continues struggling with its third consecutive year of declining revenue and net losses, with stock down ~44% over the ...
Law firm investigating potential claims against QuidelOrtho for allegedly misleading investors about COVID-19 test revenues and product launch during 2022-2024, with significant earnings miss and revenue forecast reduction in February 2024.
The global lateral flow assay market is projected to grow from $8.2 billion in 2024 to $12.6 billion by 2030, with a 7.5% CAGR. North America is expected to lead market growth, driven by advanced healthcare infrastructure and rapid diagnostic innovations.
